Navidea receives orphan drug designation from FDA for use of Lymphoseek®
Navidea announced that Lymphoseek® (technetium Tc 99m tilmanocept) Injection has been granted Orphan Drug Designation by the FDA for use in sentinel lymph node detection in patients with cancer of the head and neck. September 18, 2014